BLOOD Centers Act

HR 5791, the BLOOD Centers Act, creates a 30-day expedited approval process for blood centers seeking to add apheresis collection devices to existing biologics licenses. It directly affects blood centers operating under FDA biologics licenses that already manage multiple locations or hold accredited status. The bill requires the FDA to approve such applications within 30 days unless safety concerns exist at the specific location or the center has systemic safety failures elsewhere. This streamlines the process for expanding blood collection capabilities without compromising safety standards.